<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00934752</url>
  </required_header>
  <id_info>
    <org_study_id>CL0013-01</org_study_id>
    <nct_id>NCT00934752</nct_id>
  </id_info>
  <brief_title>De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions</brief_title>
  <official_title>An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll patients with angiographically significant coronary de novo lesions.
      Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after
      bare-metal stenting (BMS). The purpose is to assess the feasibility, safety and efficacy of
      the Lutonix Catheter for treatment of de novo coronary artery stenosis using two distinct
      treatment strategies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent stent volume obstruction as measured by optical coherence tomography (OCT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent Malposition</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Lumen Area</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Symmetry</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Expansion</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Lutonix Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Paclitaxel-Coated Balloon</intervention_name>
    <description>Percutaneous transluminal coronary angioplasty (PCTA)</description>
    <arm_group_label>Lutonix Catheter</arm_group_label>
    <other_name>Drug Coated Balloon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant/non-breast feeding Female ≥ 18 years of age. Women of
             childbearing potential must have a negative pregnancy test (within 7 days of the
             procedure);

          -  Documented stable angina pectoris Canadian Cardiovascular Society Classification
             (CCSC) 1-4, unstable angina pectoris with documented ischemia (Braunwald I-II) or
             documented silent ischemia;

          -  Left ventricular ejection fraction (LVEF) ≥ 25%;

          -  Patient is an acceptable candidate for PTCA, stenting, and emergent coronary artery
             bypass grafting (CABG);

          -  Patient is willing to provide informed consent and comply with follow-up visits and
             testing schedule;

          -  Target lesion is a de novo lesion in a native coronary artery vessel;

          -  Initial stenosis is ≥ 50% and &lt; 100% by visual estimate or quantitative coronary
             angiography (QCA);

          -  Reference Vessel Diameter (RVD) is ≥ 2.5 and ≤ 3.25 prior to predilation;

          -  Target lesion is ≤18mm in length and can be treated in its entirety by no more than 1
             single Lutonix Catheter balloon and 1 single BMS;

          -  Guidewire is able to cross lesion and be placed in distal vessel prior to enrollment;

          -  Enrollment permitted after successful treatment of 1 non-study lesion in a single
             other non-study vessel (not in the same vascular territory as the study lesion).
             Successful treatment is defined as ≤ 30% residual stenosis with Thrombolysis in
             Myocardial Infarction (TIMI) Grade III flow and not evidence of dissection.

        Exclusion Criteria:

          -  History of stroke within past 6 months;

          -  History of myocardial infarction (MI) or thrombolysis within 72 hours of
             randomization;

          -  Prior vascular brachytherapy;

          -  Uncontrollable allergies to procedure medications, materials or contrast;

          -  Angiographic evidence of thrombus or dissection within the target vessel;

          -  Intervention of another coronary lesion ≤ 60 days before index procedure day or
             planned following index procedure;

          -  Target lesion is planned to be treated with something other than PTCA and stent (i.e.,
             cutting-balloon, atherectomy, vascular brachytherapy (VBT), etc.);

          -  Target lesion is in the Left Main and has excessive calcification or tortuosity or
             involves bifurcation disease of vessel ≥ 2.5mm;

          -  Known sensitivity or has received paclitaxel or other antimitogenic agent within 12
             months prior to target vessel treatment;

          -  Patient has any previous intervention (PTCA, stent, etc.) of the target coronary
             vessel;

          -  Any medical condition, in the investigators opinion, that should preclude the patient
             from the study or patient has a life expectancy less than 24 months;

          -  Known creatine kinase-MB (CKMB) &gt; 2x upper limit of normal (ULN) or positive Troponin;

          -  Creatinine &gt; 2.0 mg/dl;

          -  Leukocyte &lt; 3500/mL;

          -  Platelet &lt; 100,000 mL or &gt; 750,000 mL;

          -  Currently taking or must resume warfarin;

          -  Patient is contraindicated for antiplatelet therapy or it will need to be withdrawn
             for a planned procedure;

          -  The subject is currently participating in another investigational drug or device
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. P.W.J C. Serruys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Universtiy Medical Center; Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catherina Zeikenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thorax Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994 Aug 25;331(8):489-95.</citation>
    <PMID>8041413</PMID>
  </reference>
  <reference>
    <citation>Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003 Aug 19;108(7):788-94. Epub 2003 Aug 4.</citation>
    <PMID>12900339</PMID>
  </reference>
  <reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </reference>
  <reference>
    <citation>Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007 Jan 10;297(2):159-68. Epub 2006 Dec 5.</citation>
    <PMID>17148711</PMID>
  </reference>
  <reference>
    <citation>Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation. 1999 Aug 24;100(8):799-806.</citation>
    <PMID>10458714</PMID>
  </reference>
  <reference>
    <citation>Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. N Engl J Med. 1998 Dec 3;339(23):1672-8.</citation>
    <PMID>9834304</PMID>
  </reference>
  <reference>
    <citation>Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994 Aug 25;331(8):496-501.</citation>
    <PMID>8041414</PMID>
  </reference>
  <reference>
    <citation>Gonzalo N, Garcia-Garcia HM, Serruys PW, Commissaris KH, Bezerra H, Gobbens P, Costa M, Regar E. Reproducibility of quantitative optical coherence tomography for stent analysis. EuroIntervention. 2009 Jun;5(2):224-32.</citation>
    <PMID>19527980</PMID>
  </reference>
  <reference>
    <citation>Holmes DR Jr, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006 Mar 15;295(11):1264-73. Epub 2006 Mar 12.</citation>
    <PMID>16531619</PMID>
  </reference>
  <reference>
    <citation>Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006 Jul 4;48(1):193-202. Epub 2006 May 5.</citation>
    <PMID>16814667</PMID>
  </reference>
  <reference>
    <citation>King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL; ACC/AHA/SCAI, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008 Jan 15;51(2):172-209. doi: 10.1016/j.jacc.2007.10.002.</citation>
    <PMID>18191745</PMID>
  </reference>
  <reference>
    <citation>Lee MS, Pessegueiro A, Zimmer R, Jurewitz D, Tobis J. Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era. J Invasive Cardiol. 2008 Aug;20(8):401-3.</citation>
    <PMID>18688064</PMID>
  </reference>
  <reference>
    <citation>Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007 Mar 8;356(10):1020-9. Epub 2007 Feb 12.</citation>
    <PMID>17296821</PMID>
  </reference>
  <results_reference>
    <citation>Lansky AJ, Popma JJ, Cutlip D, Ho KK, Abizaid AS, Saucedo J, Zhang Y, Senerchia C, Kuntz RE, Leon MB, Baim DS. Comparative analysis of early and late angiographic outcomes using two quantitative algorithms in the Balloon versus Optimal Atherectomy Trial (BOAT). Am J Cardiol. 1999 Jun 15;83(12):1611-6.</citation>
    <PMID>10392863</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo stenotic lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

